Title of article :
VA-Wide, Multicenter Verification Study of the Cepheid Xpert SARS-CoV-2 Assay
Author/Authors :
Obeidat, Mohammad Department of Pathology - University of Iowa Carver College of Medicine, IA, USA , Frank, Amy R. Pathology and Laboratory Medicine - Iowa City VA Healthcare System, IA, USA , Icardi, Michael S. Department of Pathology - University of Iowa Carver College of Medicine, IA, USA , Klutts, J. Stacey Department of Pathology - University of Iowa Carver College of Medicine, IA, USA
Pages :
4
From page :
1
To page :
4
Abstract :
Early in the Severe Acute Respiratory Syndrome Coronavirus 2 pandemic, there was a progressive increase in diagnostic demands that developed within a relatively short period of time. On February 4, 2020, the Secretary of Health and Human Services issued the Emergency Use Authorization for in vitro diagnostics assays for the Severe Acute Respiratory Syndrome Coronavirus 2 virus. Subsequently, multiple assays were approved under the Emergency Use Authorization, including the Cepheid Xpert SARS-CoV-2 assay. Presented here is a description of the nationally coordinated verification study of the Cepheid assay that was performed within the Veteran’s Affairs Health System. This coordinated study helped to expedite the verification process for a majority of the Veteran’s Affairs system labs, preserved precious system resources, and highlighted the power of a national medical system in response to an emergency.
Keywords :
Severe Acute Respiratory Syndrome Coronavirus 2 , COVID-19 , polymerase chain reaction , Cepheid , verification , validation , Veteran’s Affairs (VA) health system
Journal title :
Academic Pathology
Serial Year :
2021
Full Text URL :
Record number :
2615319
Link To Document :
بازگشت